Name

Name

Steve Buck

Personal details

Location

USA

Web

https://www.medixocentre.com/hepatitis/velpanat-tablets

Short Bio

Velpanat is the first pan-genotypic (for all genotypes, 1 to 6) combination drug for the treatment of chronic viral hepatitis C with a regimen of 1 tablet per day. The composition of the drug includes a nucleotide analogue of the Sofosbuvir polymerase inhibitor at a dosage of 400 mg and a pangenotypic NS5A inhibitor veltapasvir at a dosage of 100 mg. The recommended duration of the Epclusa course is 12 weeks without ribavirin for patients without cirrhosis or with compensated liver cirrhosis (Child-Pugh A).

History

Member for

5 years 10 months